LRFFT2 cell

A cell and antigen epitope technology, applied in the field of LRFFT2 cells and its preparation, can solve the problems of lack of patient antigens, lack of accurate and effective analysis, etc., and achieve strong target specificity, unlimited killing ability, and high killing efficiency Effect

Active Publication Date: 2019-04-26
BEIJING DCTY BIOTECH CO LTD +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is a general lack of accurate and effective analysis of patient antigens

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • LRFFT2 cell
  • LRFFT2 cell
  • LRFFT2 cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0060] The present invention is described below through specific embodiments. Unless otherwise specified, the technical means used in the present invention are methods known to those skilled in the art. In addition, the embodiments should be considered as illustrative rather than limiting the scope of the invention, the spirit and scope of which is defined only by the claims. For those skilled in the art, on the premise of not departing from the spirit and scope of the present invention, various changes or modifications to the material components and dosage in these embodiments also belong to the protection scope of the present invention.

[0061] The technical solution is detailed as follows:

[0062] 1. Epitope prediction

[0063] 1) Use the peripheral blood of lung cancer patients for ctDNA sequencing and HLA typing detection;

[0064] 2) Use software to analyze the sequencing information: compare the ctDNA sequencing results with the genome of normal cells, and screen o...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an LRFFT2 cell. According to the LRFFT2 cell, human peripheral blood is used for carrying out ctDNA sequencing or carrying out whole exome sequencing on tumor tissue, mutationsites are screened out for antigen epitope prediction, and mutant polypeptide expression gene sequences are connected and synthesized; meanwhile, a lentivirus vector is constructed, lentivirus is packaged, an APC cell is transfected, the modification of a specific LV cell is completed, co-culture is carried out with a PBMC separated from the peripheral blood in vitro, effective polypeptide is screened out, and the second impact of stimulation of the effective polypeptide is accurate, so that a common T cell is transformed into an RFF cell with more accurate killing capability; transformation is carried out by utilizing a TCR-T technical principle; and immunosuppressive signal sealing is carried out on the transformed T cell in vitro by using an antibody drug, so that the specific killing Tcell is accurately protected from in-vivo suppression, and the killing force of the T cell on a tumor cell is improved, and therefore the LRFFT2 cell with better attack and defense functions is obtained. The LRFFT2 cell can be widely applied to individualized accurate treatment of solid tumors.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a LRFFT2 cell and a preparation method thereof. Background technique [0002] At present, in terms of tumor-specific immunotherapy, the existing LAK, DC, CIK, and DC-CIK cells and methods have basically been proved to be ineffective, while NK, CAR-NK, TIL and other cell technologies have yet to mature. CAR- T cells also have shortcomings in safety and solid tumor therapy. In the prior art, DCs are generally modified to present T cells to produce specific killing. Some laboratories are trying to use viruses as vectors to transfect and present T cells to induce specific killing of T cells. We have also used mutant hybrid peptides to directly stimulate PBMCs to induce T cells. There are also laboratories using TCR-T technology to target the presentation of MAGE A3 antigen. [0003] The above treatment methods are immature, especially the in vitro induction of DC cells an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/10A61P35/00
CPCA61P35/00C12N5/0636C12N9/22C12N15/86C12N15/907C07K14/7051C12N2510/00C12N2740/15043C12N2810/10C12N2800/80C12N2310/20C12N15/113C12N2740/16043C12N7/00C12N15/11C12N2501/998C12N2502/11G01N33/505
Inventor 焦顺昌张嵘张天赋周子珊解佳森吴子明彭刚
Owner BEIJING DCTY BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap